Tapering Protocol for Venlafaxine

Introduction to Tapering

The American College of Physicians recommends that venlafaxine must be tapered when discontinuing treatment because a withdrawal syndrome has been well-documented, which can include nausea, dizziness, anxiety, insomnia, and dysphoria 1, 2
Abrupt discontinuation can cause significant physical and affective symptoms including tremor, diaphoresis, agitation, insomnia, diffuse pain, dysphoria, and anxiety 3

For patients on 37.5mg daily, the Mayo Clinic recommends implementing a slow, gradual reduction over several weeks, starting with a reduction to 37.5mg every other day for 1-2 weeks, then discontinuing 3
The taper should extend over a minimum of 2-4 weeks to minimize discontinuation effects, according to the Mayo Clinic Proceedings 4

Common withdrawal symptoms to anticipate and manage include physical symptoms such as nausea, headache, dizziness, diaphoresis, insomnia, tremor, and affective symptoms such as dysphoria, anxiety, irritability, and anhedonia 2, 3
The Mayo Clinic recommends providing supportive care and symptom management, including addressing insomnia, anxiety, and mood symptoms proactively, ensuring adequate clinician time and support throughout the taper, and considering non-pharmacological interventions including counseling and patient education about expected symptoms 3, 4

Withdrawal symptoms typically emerge within days of dose reduction and may persist for weeks, requiring patient education and reassurance that symptoms are manageable and temporary, as noted by the Mayo Clinic Proceedings 3
Slower tapers, extending over months, may be appropriate for patients who have been on venlafaxine for prolonged periods or who experience significant withdrawal symptoms with faster tapers, according to the Mayo Clinic Proceedings 3